Literature DB >> 27738376

Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required.

Robert M Nevels1, Samuel T Gontkovsky1, Bryman E Williams1.   

Abstract

Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various anxiety disorders, it quickly gained a sizable share of the antidepressant prescription market. By the late 1990s, paroxetine frequently was being associated with serious drug interactions and medication side effects. Most significantly, in a major Canadian epidemiological study examining the relationship between antidepressants and diseases, paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period. Though re-analyses of this investigation discounted the magnitude of these findings, other studies have associated paroxetine with numerous side effects and adverse events not reported in clinical trials. Among these are effects on male fertility, birth defects, gestational hypertension, prolonged QT interval in infants, hyperprolactinemia, cognitive impairment in the elderly, autism, sexual side effects, weight gain, and suicidality, aggression, and akathisia in children and adolescents. Paroxetine has the highest inhibitory constant for the P450 2D6 isoenzyme of all antidepressants (Ki = 0.065-4.65 micromoles). This high affinity explains its high inhibitory interaction profile with substrates for 2D6. Paroxetine's potent 2D6 inhibition also implies that significant inhibition of the metabolism of 2D6 carcinogen substrates occurs which implies an increased probability of oncogenesis. Through 2D6 inhibition, tamoxifen metabolism is inhibited, which has been found to increase the risk of dying from breast cancer over a five-year period in women on both medications. Paroxetine also is a potent inhibitor of 3A4 with multiple 3A4 substrate interactions. Paroxetine has the highest known affinity for the serotonin transporter (0.13 nanomoles) of any currently used antidepressant. These characteristics and their potential negative consequences along with other adverse effects are considered and weighed against paroxetine's efficacious antidepressant and anxiolytic effects.

Entities:  

Keywords:  depression; drug; psychiatry; serotonin; side effects

Year:  2016        PMID: 27738376      PMCID: PMC5044489     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  50 in total

Review 1.  The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects.

Authors:  Pär Hallberg; Viktoria Sjöblom
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

2.  Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy.

Authors:  Gillian E Hanley; Kate Smolina; Barbara Mintzes; Tim F Oberlander; Steven G Morgan
Journal:  Obstet Gynecol       Date:  2016-03       Impact factor: 7.661

3.  Cognitive effects of paroxetine in older depressed patients.

Authors:  R D Nebes; B G Pollock; B H Mulsant; M A Butters; M D Zmuda; C F Reynolds
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

4.  The relationship between antidepressant prescription rates and rate of early adolescent suicide.

Authors:  Robert D Gibbons; Kwan Hur; Dulal K Bhaumik; J John Mann
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 5.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

Review 6.  Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis.

Authors:  Daniel G Hackam; Marko Mrkobrada
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

7.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

8.  Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.

Authors:  Orna Diav-Citrin; Svetlana Shechtman; Dafna Weinbaum; Rebecka Wajnberg; Meytal Avgil; Elena Di Gianantonio; Maurizio Clementi; Corinna Weber-Schoendorfer; Christof Schaefer; Asher Ornoy
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

9.  Use of antidepressant medications in relation to the incidence of breast cancer.

Authors:  D Fulton-Kehoe; M A Rossing; C Rutter; M T Mandelson; N S Weiss
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

Review 10.  Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Authors:  Jennita Reefhuis; Owen Devine; Jan M Friedman; Carol Louik; Margaret A Honein
Journal:  BMJ       Date:  2015-07-08
View more
  14 in total

1.  Chemical and structural investigation of the paroxetine-human serotonin transporter complex.

Authors:  Jonathan A Coleman; Vikas Navratna; Daniele Antermite; Dongxue Yang; James A Bull; Eric Gouaux
Journal:  Elife       Date:  2020-07-03       Impact factor: 8.140

2.  SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.

Authors:  Kelly E Dunham; B Jill Venton
Journal:  J Neurochem       Date:  2022-07-09       Impact factor: 5.546

3.  A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants.

Authors:  Courtney De Vries; Svetla Gadzhanova; Matthew J Sykes; Michael Ward; Elizabeth Roughead
Journal:  Drug Saf       Date:  2020-12-22       Impact factor: 5.606

4.  Antidepressants, withdrawal, and addiction; where are we now?

Authors:  Sameer Jauhar; Joseph Hayes; Guy M Goodwin; David S Baldwin; Philip J Cowen; David J Nutt
Journal:  J Psychopharmacol       Date:  2019-05-21       Impact factor: 4.562

Review 5.  Paroxetine-Overview of the Molecular Mechanisms of Action.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Łukasz Fijałkowski; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

6.  Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish.

Authors:  Michael Edbert Suryanto; Gilbert Audira; Boontida Uapipatanakul; Akhlaq Hussain; Ferry Saputra; Petrus Siregar; Kelvin H-C Chen; Chung-Der Hsiao
Journal:  Cells       Date:  2021-03-26       Impact factor: 6.600

7.  PhenCards: a data resource linking human phenotype information to biomedical knowledge.

Authors:  James M Havrilla; Cong Liu; Xiangchen Dong; Chunhua Weng; Kai Wang
Journal:  Genome Med       Date:  2021-05-25       Impact factor: 11.117

8.  Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole.

Authors:  Mikhail V Voronin; Yulia V Vakhitova; Inna P Tsypysheva; Dmitry O Tsypyshev; Inna V Rybina; Rustam D Kurbanov; Elena V Abramova; Sergei B Seredenin
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

9.  Antidepressant Paroxetine Exerts Developmental Neurotoxicity in an iPSC-Derived 3D Human Brain Model.

Authors:  Xiali Zhong; Georgina Harris; Lena Smirnova; Valentin Zufferey; Rita de Cássia da Silveira E Sá; Fabiele Baldino Russo; Patricia Cristina Baleeiro Beltrao Braga; Megan Chesnut; Marie-Gabrielle Zurich; Helena T Hogberg; Thomas Hartung; David Pamies
Journal:  Front Cell Neurosci       Date:  2020-02-21       Impact factor: 5.505

10.  Quantifying and Categorizing ADRs in Psychiatric Residential Long-Stay Patients Utilizing UKU-SERS Scale.

Authors:  Joelin Mathew; Amruta Varghese; Manjusha Sajith
Journal:  Indian J Psychol Med       Date:  2020-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.